4577 Daito Pharmaceutical Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4577

TSE Prime

Daito Pharmaceutical Co.,Ltd.

2,025

JPY

(+0.35%)

Dec 23, 3:30 pm JST

12.93

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
May, 2021	48,714	5,908	6,067	4,246	282.8	41.82	Jul 14, 2021	J-GAAP
May, 2022	43,464	6,553	6,729	4,668	304.9	54.55	Jul 14, 2022	J-GAAP
May, 2023	45,101	5,207	5,169	3,600	227.6	54.55	Jul 14, 2023	J-GAAP
May, 2024	46,895	3,894	3,923	3,295	210.0	60	Jul 12, 2024	J-GAAP
May, 2025 Guidance	49,000	3,500	3,500	2,300	150.4	70	Jul 12, 2024	J-GAAP
YoY	+4.5%	-10.1%	-10.8%	-30.2%	-28.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
May, 2020	Jul 12, 2019	43,500	4,700	4,750	3,300	36.36	J-GAAP
	Apr 14, 2020	43,500	4,700	4,750	3,300	41.82	J-GAAP
Results	Jul 10, 2020	44,991	5,357	5,462	3,944	41.82	J-GAAP
May, 2021	Jul 10, 2020	Available in future release
	Apr 14, 2021
Results	Jul 14, 2021
May, 2022	Jul 14, 2021
	Apr 14, 2022
Results	Jul 14, 2022
May, 2023	Jul 14, 2022
Results	Jul 14, 2023
May, 2024	Jul 14, 2023
	Jun 25, 2024
Results	Jul 12, 2024
May, 2025	Jul 12, 2024	49,000	3,500	3,500	2,300	70	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
May, 2005	14,172	－	Available in future release
May, 2006	15,542	+9.7
May, 2007	16,990	+9.3
May, 2008	20,756	+22.2
May, 2009	21,522	+3.7
May, 2010	22,678	+5.4
May, 2011	25,225	+11.2
May, 2012	27,151	+7.6
May, 2013	28,956	+6.6
May, 2014	31,196	+7.7
May, 2015	34,058	+9.2
May, 2016	36,370	+6.8
May, 2017	37,984	+4.4
May, 2018	39,875	+5.0
May, 2019	41,134	+3.2
May, 2020	44,991	+9.4
May, 2021	48,714	+8.3
May, 2022	43,464	-10.8
May, 2023	45,101	+3.8
May, 2024	46,895	+4.0
May, 2025 Guidance	49,000	+4.5	3,500	-10.1	3,500	-10.8	150.4	-28.4

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
May, 2023	45,101	5,207	11.6	7.35	5.31	0.67	227.6
May, 2024	46,895	3,894	8.30	6.41	4.44	0.63	210.0
May, 2025 Guidance	49,000	3,500	7.14	4.42	2.81	0.60	150.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	48,714	6,553	6,729	4,668	304.9
Fiscal Year	May, 2021	May, 2022	May, 2022	May, 2022	May, 2022

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jun - Nov, 2021	22,463	3,877	3,981	2,777	183.7	22.73	Jan 14, 2022	J-GAAP
Jun - Nov, 2022	23,367	2,826	2,752	1,762	111.3	27.27	Jan 13, 2023	J-GAAP
Jun - Nov, 2023	24,110	2,289	2,314	1,552	98.2	30	Jan 12, 2024	J-GAAP
Jun - Nov, 2024 Guidance	ー	ー	ー	ー	－	35	Jul 12, 2024	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Nov, 2021	Jul 14, 2021	ー	ー	ー	ー	22.73	J-GAAP
- - - - Results	Jan 14, 2022	22,463	3,877	3,981	2,777	22.73	J-GAAP
Nov, 2022	Jul 14, 2022	Available in future release
Results	Jan 13, 2023
Nov, 2023	Jul 14, 2023
Results	Jan 12, 2024
Nov, 2024	Jul 12, 2024	ー	ー	ー	ー	35	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
May, 2022	6,553	-30	4,370	-4,400	989	4,381	6.75	J-GAAP
May, 2023	5,207	-1,411	4,155	-5,566	616	3,607	5.11	J-GAAP
May, 2024	3,894	-748	5,182	-5,930	-183	2,727	3.51	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jun - Aug, 2022	12,041	1,501	1,475	946	59.7	53.6	Oct 13, 2022	J-GAAP
Jun - Aug, 2023	12,178	1,080	1,092	683	43.3	47.2	Oct 12, 2023	J-GAAP
Jun - Aug, 2024	12,678	849	983	618	40.4	ー	Oct 11, 2024	J-GAAP
YoY	+4.1%	-21.4%	-10.0%	-9.5%	-6.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Sep - Nov, 2022	11,326	1,325	1,277	816	51.6	11.7	Jan 13, 2023	J-GAAP
Dec - Feb, 2022	11,203	1,280	1,325	898	56.8	11.4	Apr 13, 2023	J-GAAP
Mar - May, 2023	10,531	1,101	1,092	940	59.4	10.5	Jul 14, 2023	J-GAAP
Jun - Aug, 2023	12,178	1,080	1,092	683	43.3	8.9	Oct 12, 2023	J-GAAP
Sep - Nov, 2023	11,932	1,209	1,222	869	55.0	10.1	Jan 12, 2024	J-GAAP
Dec - Feb, 2023	10,552	816	808	787	49.9	7.7	Apr 12, 2024	J-GAAP
Mar - May, 2024	12,233	789	801	956	60.9	6.4	Jul 12, 2024	J-GAAP
Jun - Aug, 2024	12,678	849	983	618	40.4	6.7	Oct 11, 2024	J-GAAP
YoY	+4.1%	-21.4%	-10.0%	-9.5%	-6.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Sep - Nov, 2019	11,595	+11.4	Available in future release
Dec - Feb, 2019	11,119	+8.4
Mar - May, 2020	10,619	-1.1
Jun - Aug, 2020	13,703	+17.5
Sep - Nov, 2020	12,332	+6.4
Dec - Feb, 2020	11,800	+6.1
Mar - May, 2021	10,879	+2.4
Jun - Aug, 2021	11,746	-14.3
Sep - Nov, 2021	10,717	-13.1
Dec - Feb, 2021	11,120	-5.8
Mar - May, 2022	9,881	-9.2
Jun - Aug, 2022	12,041	+2.5
Sep - Nov, 2022	11,326	+5.7
Dec - Feb, 2022	11,203	+0.7
Mar - May, 2023	10,531	+6.6
Jun - Aug, 2023	12,178	+1.1
Sep - Nov, 2023	11,932	+5.4
Dec - Feb, 2023	10,552	-5.8
Mar - May, 2024	12,233	+16.2
Jun - Aug, 2024	12,678	+4.1	849	-21.4	983	-10.0	40.4	-6.7

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	13,703	2,360	2,419	1,825	121.0
Fiscal Year	Aug, 2020	Aug, 2021	Aug, 2021	Aug, 2021	Aug, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
May, 2022	3,310.34	72.8	64,939	47,298	32,338	0.07	Jul 14, 2022	J-GAAP
May, 2023	3,206.50	71.8	70,552	50,672	35,006	0.10	Jul 14, 2023	J-GAAP
May, 2024	3,404.70	67.0	77,708	52,068	37,087	0.13	Jul 12, 2024	J-GAAP
Jun - Aug, 2024	ー	63.5	81,929	52,002	36,381	0.23	Oct 11, 2024	J-GAAP

Daito Pharmaceutical Co.,Ltd.(4577) Financial Results